Skip to main content
Top
Published in: Cancer Causes & Control 10/2019

01-10-2019 | Neurofibromatosis | Original Paper

Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)

Authors: Nicolas Vidart d’Egurbide Bagazgoïtia, Helen D. Bailey, Laurent Orsi, Léa Guerrini-Rousseau, Anne-Isabelle Bertozzi, Cécile Faure-Conter, Pierre Leblond, Isabelle Pellier, Claire Freycon, François Doz, Stéphanie Puget, Stéphane Ducassou, Brigitte Lacour, Jacqueline Clavel

Published in: Cancer Causes & Control | Issue 10/2019

Login to get access

Abstract

Purpose

Although some specific genetic syndromes such as neurofibromatosis (NF) have been identified as risk factor of childhood brain tumors (CBT), the potential role of inherited susceptibility in CBT has yet to be elucidated.

Methods

To further investigate this, we conducted a pooled analysis of two nationwide case–control studies ESCALE and ESTELLE. The mothers of 509 CBT cases and 3,102 controls aged under 15 years who resided in France at diagnosis/interview, frequency-matched by age and gender, responded to a telephone interview conducted by trained interviewers. Pooled odds ratio (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression.

Results

CBT was significantly associated with the family history of cancer in relatives (OR 1.2, 95% CI 1.0–1.5). The OR was slightly higher for maternal relatives than for paternal relatives, and when at least two relatives had a history of cancer. CBT was significantly associated with a family history of brain tumor (OR 2.1, 95% CI 1.3–3.7). This association seemed stronger for first-degree relatives (mother, father, and siblings), for whom, by contrast, no association was seen for cancers other than CBT. No specificity by CBT subtypes or by age of the children were found for any of these findings.

Conclusion

Our findings support the hypothesis of a familial susceptibility of CBT, not due to being a known NF carrier.
Literature
10.
go back to reference Kuijten RR, Bunin GR, Nass CC, Meadows AT (1990) Gestational and familial risk factors for childhood astrocytoma: results of a case–control study. Cancer Res 50:2608–2612PubMed Kuijten RR, Bunin GR, Nass CC, Meadows AT (1990) Gestational and familial risk factors for childhood astrocytoma: results of a case–control study. Cancer Res 50:2608–2612PubMed
12.
go back to reference Gold EB, Leviton A, Lopez R et al (1994) The role of family history in risk of childhood brain tumors. Cancer 73:1302–1311CrossRefPubMed Gold EB, Leviton A, Lopez R et al (1994) The role of family history in risk of childhood brain tumors. Cancer 73:1302–1311CrossRefPubMed
27.
go back to reference Ivanovich J, Babb S, Goodfellow P et al (2002) Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 8:1849–1856PubMed Ivanovich J, Babb S, Goodfellow P et al (2002) Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 8:1849–1856PubMed
Metadata
Title
Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)
Authors
Nicolas Vidart d’Egurbide Bagazgoïtia
Helen D. Bailey
Laurent Orsi
Léa Guerrini-Rousseau
Anne-Isabelle Bertozzi
Cécile Faure-Conter
Pierre Leblond
Isabelle Pellier
Claire Freycon
François Doz
Stéphanie Puget
Stéphane Ducassou
Brigitte Lacour
Jacqueline Clavel
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 10/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01214-x

Other articles of this Issue 10/2019

Cancer Causes & Control 10/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine